This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
By This Author:
Page 3 of 588

Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.

By Adam Feuerstein

It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.

09:58AM 03/11/15

Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses

By Adam Feuerstein

Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.

11:10AM 03/10/15

Ocular Therapeutix Eye-Pain Plug Benefits Still Unclear

By Adam Feuerstein

Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.

10:17AM 03/10/15

CTI Biopharma Posts Positive Myelofibrosis Study Results

By Adam Feuerstein

CTI Biopharma's experimental drug pacritinib significantly reduced the spleen size in patients with myelofibrosis compared to patients treated with best alternative care.

08:15AM 03/09/15

Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

05:30AM 03/06/15

AbbVie Buys Pharmacyclics for $21B to Get Half of Big Cancer Drug

By Adam Feuerstein

AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion.

10:05AM 03/05/15

AbbVie Spending Historic Amount of Cash to Buy Half of a Cancer Drug

By Adam Feuerstein

The $21 billion price tag for Pharmacylics only earns AbbVie rights to 50% of the blood cancer drug Imbruvica.

06:38AM 03/05/15

Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer

By Adam Feuerstein

The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.

01:47PM 03/04/15

Regulators Want Drug Companies to Be Honest About FDA

By Adam Feuerstein

The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.

01:08PM 03/04/15

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

By Adam Feuerstein

Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.

11:51AM 03/03/15

Page 3 of 588

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs